ReviewAllergologie select2024
Allergen immunotherapy for allergic asthma.
Review in Allergologie select, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre-Seasonal Short Courses of Allergen-Specific Immunotherapy: A Long-Term Open-Label Extension Study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Trial
- [Effect of the number of sensitizing allergens on the efficacy of subcutaneous immunotherapy and quality of life in children with asthma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Short-Course Subcutaneous Immunotherapy With Mannan-Conjugated Birch Pollen Allergoids: Consistent Clinical and Immunological Improvements.Clinical and translational allergy · 2026Article
- Steroid Sparing Effect of 300IR House Dust Mite Sublingual Immunotherapy Tablet in Mite Allergic Rhinitis.Clinical and translational allergy · 2026Article
- Article
- Exploring the indicative role of ACT score in improving lung function in asthmatic children undergoing dust mite immunotherapy.BMC pediatrics · 2025Article
- Recent progress on nanotechnologies for enhancing blood-brain barrier permeability.Smart molecules : open access · 2025Review
- Development of fast-dissolving sublingual nanofibers containing allergen and curcumin for immune response modulation in a mouse model of allergic rhinitis.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Efficacy of subcutaneous specific immunotherapy for allergic rhinitis combined with asthma: a retrospective analysis.American journal of translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remission is the goal of modern asthma treatment. Allergen immunotherapy (AIT) is an essential component in the armamentarium of personalized asthma therapy. Subcutaneous AIT (SCIT) or sublingual AIT (SLIT) offer the possibility to prevent asthma in patients with allergic rhinitis (reduction of the risk of developing asthma) and the possibility to achieve remission in patients with allergic asthma. Accordingly, AIT should always be considered in patients with asthma and a documented, clinically relevant allergy. However, precise phenotyping of the patient is an essential prerequisite for a success of AIT in asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.